Associated Disease Details
| Disease ID: | I15 |
| DO ID: | 1290 |
| Disease Name: | Bone disease |
| Definition: | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease |
| Synonyms: | Osteomalacia; Osteoporosis; Osteoporosis, Postmenopausal; Arthritis; Arthritis, Gouty; Degenerative polyarthritis; Rheumatoid Arthritis; Gout; Hyperuricemia; osteoarthritis |
| Class: | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease |
| Related Drugs: | Ergocalciferol; Allopurinol; Aspirin; Salsalate |
| Mechanism: | Our data show that NAFLD is significantly associated with osteoporosis as well as bone fractures in a large cohort of patients followed in German general practices. This finding suggests that NAFLD patients might benefit from improved monitoring for the occurrence of bone demineralization and osteoporosis, which in turn could trigger preventive therapeutic measures. |
| Reference (PMIDs): | 34710938 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D008 | Alpha-tocopherol | Chemical drug | DB00163 | NR1I2; ALOX5; DGKA | -- | Under clinical trials | Details |
| D054 | Calcitriol | Supplement | DB00136 | -- | -- | Under clinical trials | Details |
| D055 | Calcium | Chemical drug | DB01373 | CAST; COMP; CP; BMP4; MGP | -- | Under clinical trials | Details |
| D126 | Ergocalciferol | Supplement | DB00153 | VDR agonist; VDR modulator | Calcium regulator; Vitamin source drug | Under clinical trials | Details |
| D139 | Fluconazole | Chemical drug | DB00196 | CYP51A1 inhibitor | Antifungal | Under clinical trials | Details |
| D160 | Growth Hormone | Biological drug | DB00052 | GHR ligand; PRLR ligand | -- | Under clinical trials | Details |
| D199 | L-alanine | Chemical drug | DB00160 | KYNU | -- | Failed in clinical trials | Details |
| D203 | Levothyroxine | Chemical drug | DB00451 | THRA agonist; THRB agonist | Anti-fibrosis | Under clinical trials | Details |
| D264 | Pantoprazole | Chemical drug | DB00213 | gastric H-K-ATPase inhibitor; ATP4B inhibitor; ATP4A inhibitor | Gastrointestinal drug | Under clinical trials | Details |
| D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R0006 | DB00016 | approved | biotech | Erythropoietin | Therapeutic strategy associated | Details |
| R0007 | DB00017 | approved; investigational | biotech | Salmon calcitonin | Indication associated | Details |
| R0009 | DB00026 | approved | biotech | Anakinra | Therapeutic strategy associated | Details |
| R0010 | DB00028 | approved; investigational | biotech | Human immunoglobulin G | Indication associated | Details |
| R0027 | DB00091 | approved; investigational; vet_approved | small molecule | Cyclosporine | Therapeutic strategy associated | Details |
| R0046 | DB00138 | approved; nutraceutical | small molecule | Cystine | Therapeutic strategy associated | Details |
| R0048 | DB00141 | approved; investigational; nutraceutical | small molecule | N-Acetylglucosamine | Indication associated | Details |
| R0049 | DB00146 | approved; nutraceutical | small molecule | Calcifediol | Indication associated | Details |
| R0057 | DB00169 | approved; nutraceutical | small molecule | Cholecalciferol | Therapeutic strategy associated | Details |
| R0058 | DB00170 | approved; nutraceutical | small molecule | Menadione | Therapeutic strategy associated | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00266 | 35160329 | J Clin Med | Influence of Body Mass Index, Cancer Type and Treatment on Long-Term Metabolic and Liver Outcomes in Childhood Cancer Survivors. | Details |
| A00311 | 35142615 | Diagn Interv Radiol | Proton density fat fraction: magnetic resonance imaging applications beyond the liver. | Details |
| A00347 | 35126317 | Front Endocrinol (Lausanne) | Prevalence and Trends in Low Bone Density, Osteopenia and Osteoporosis in U.S. Adults With Non-Alcoholic Fatty Liver Disease, 2005-2014. | Details |
| A00669 | 35008925 | Int J Mol Sci | Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future. | Details |
| A00687 | 35003513 | Oxid Med Cell Longev | TNF-Like Ligand 1 Aberrance Aggravates Nonalcoholic Steatohepatitis via M1 Macrophage Polarization. | Details |
| A00738 | 34983596 | Chin Med | Traditional Chinese medicine Lingguizhugan decoction ameliorate HFD-induced hepatic-lipid deposition in mice by inhibiting STING-mediated inflammation in macrophages. | Details |
| A00805 | 34959901 | Nutrients | Role and Treatment of Insulin Resistance in Patients with Chronic Kidney Disease: A Review. | Details |
| A01034 | 34895322 | Stem Cell Res Ther | Bone marrow derived-mesenchymal stem cell improves diabetes-associated fatty liver via mitochondria transformation in mice. | Details |
| A01283 | 34803490 | Int J Biol Sci | SOCS2 Suppresses Inflammation and Apoptosis during NASH Progression through Limiting NF-κB Activation in Macrophages. | Details |
| A01519 | 34710938 | Z Gastroenterol | Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of osteoporosis and bone fractures. | Details |
| A01543 | 34704005 | JHEP Rep | PI3Kγ promotes obesity-associated hepatocellular carcinoma by regulating metabolism and inflammation. | Details |
| A01681 | 34656648 | Metabolism | CC chemokine ligand 3 deficiency ameliorates diet-induced steatohepatitis by regulating liver macrophage recruitment and M1/M2 status in mice. | Details |
| A01806 | 34608587 | Hepatol Int | Hepatic fibrosis is associated with an increased rate of decline in bone mineral density in men with nonalcoholic fatty liver disease. | Details |
| A01881 | 34574647 | Int J Environ Res Public Health | Bone Mineral Density in Congenital Generalized Lipodystrophy: The Role of Bone Marrow Tissue, Adipokines, and Insulin Resistance. | Details |
| A01936 | 34558838 | Hepatol Commun | Dietary Risks for Liver Mortality in NAFLD: Global Burden of Disease Data. | Details |
| A01939 | 34558828 | Hepatol Commun | PRO-C3, a Serological Marker of Fibrosis, During Childhood and Correlations With Fibrosis in Pediatric NAFLD. | Details |
| A02039 | 34523053 | Inflammation | Hepatic Macrophages Express Melanoma Differentiation-Associated Gene 5 in Nonalcoholic Steatohepatitis. | Details |
| A02300 | 34431493 | J Clin Endocrinol Metab | LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia. | Details |
| A02318 | 34421825 | Front Endocrinol (Lausanne) | Decreased Sclerostin Secretion in Humans and Mice With Nonalcoholic Fatty Liver Disease. | Details |
| A02385 | 34394332 | PPAR Res | Computational Analysis of Gly482Ser Single-Nucleotide Polymorphism in PPARGC1A Gene Associated with CAD, NAFLD, T2DM, Obesity, Hypertension, and Metabolic Diseases. | Details |